The study being conducted under the Genomes2People umbrella will explore how best to introduce genetic information into the routine care of active duty service members.
Fabric disclosed partnerships with Rady Children's Institute for Genomic Medicine, the Utah Genome Project, and Genomics England's 100,000 Genomes Project.
Researchers hope that a Faroese reference genome will help drive precision medicine and shed light on population-specific disease variants.
The startup will use the funds to commercialize its single-cell analysis platform, which is based in part on droplet microfluidic technology licensed from UCSF.
Illumina Ventures will use the new funds to expand its team and invest in additional genomic and precision medicine startups.
The researchers plan to evaluate cfDNA and single cells isolated from the urine of patients who have had kidney transplants to identify signs of graft failure.
The results of the study could have implications for liquid biopsy developers that aim to pick out patients more likely to respond to immunotherapies.
Researchers retrospectively analyzed data for 278 critically ill infants tested by clinical exome sequencing at a Texas hospital over five years.
The researchers found disease-related signatures in the immune repertoire of affected patients as well as changes associated with treatment.
The companies plan to offer a service called MyMap, which will include MyGenome next-generation sequencing by Veritas and MediMap pharmacogenomic testing by Inova.
Rainbow Genomics will offer exome-sequencing based screening and diagnostic tests developed by Baylor Genetics to patients in Asia.
Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera.
Genome Medical will use the platform for ongoing examination of patients' genomic data to augment data analysis, annotation, and interpretation.
PacBio is refining the CRISPR/Cas9 capture technique with several early- access sites and plans to launch it more broadly in 2018.
Next year, the company will submit regulatory filings for the drug in two molecularly defined indications and a next-generation sequencing companion diagnostic.
Patients are organizing themselves in groups based on the molecular features driving their tumors to better advocate for themselves, raise money, and influence research.
Researchers from MSKCC reported today in JAMA that of 1,040 cancer patients referred for germline mutation testing, 18 percent had actionable variants.
Wake Forest researchers are in the midst of an ongoing precision oncology trial to see how NGS-based tumor profiling and liquid biopsy assays can be implemented.
The deal will open up more opportunities to study OmniSeq's 144-gene NGS test and Immune Report Card in real-world settings and as part of drug development trials.
Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.
Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.
Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.
The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.
In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.